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Abstract  39 
Objective:  Population-based osteoarthritis (OA) cohorts provide vital data on risk factors and out-40 
comes of OA, however the methods to define OA vary between cohorts. We aimed to provide rec-41 
ommendations for combining knee and hip OA data in extant and future population cohort studies, 42 
in order to facilitate informative individual participant level analyses. Method: International OA 43 
experts met to make recommendations on: 1) defining OA by x-ray and/or pain; 2) compare The 44 
National Health and Nutrition Examination Survey (NHANES)-type OA pain questions; 3) the 45 
comparability of the Western Ontario & McMaster Universities Osteoarthritis Index (WOMAC) 46 
scale to NHANES-type OA pain questions; 4) the best radiographic scoring method; 5) the useful-47 
ness of other OA outcome measures. Key issues were explored using new analyses in two popula-48 
tion-based OA cohorts (Multicenter Osteoarthritis Study; MOST and Osteoarthritis Initiative OAI). 49 
Results: OA should be defined by both symptoms and radiographs, with symptoms alone as a sec-50 
ondary definition. Kellgren and Lawrence (K/L) grade ≥2 should be used to define radiographic 51 
OA. The variable wording of pain questions can result in varying prevalence between 41.0 and 52 
75.4%, however questions where the time anchor is similar have high sensitivity and specificity 53 
(91.2% and 89.9% respectively). A threshold of 3 on a 0-20 scale (95% CI 2.1, 3.9) in the WOMAC 54 
pain subscale demonstrated equivalence with the preferred NHANES-type question. Conclusion: 55 
This research provides recommendations, based on expert agreement, for harmonising and combin-56 
ing OA data in existing and future population-based cohorts. 57 
 58 
Keywords: Osteoarthritis; data; harmonisation; cohort; epidemiology 59 
 60 
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Introduction 1 
 2 
OA is one of the most common causes of disability in the world (1). The prevention and 3 
management of OA is dependent on the understanding of modifiable risk factors for OA in the 4 
population at earlier stages of disease. To fully understand the risk factors for OA as well as its 5 
long-term effects, there is a need to combine data from population-based cohorts to provide 6 
sufficient statistical power. Traditional meta-analyses on OA rely on aggregate data obtained from 7 
study publications. These are vulnerable to outcome reporting and publication bias, and the quality 8 
and availability of data may vary across studies (2). An increasingly popular alternative to 9 
traditional meta-analysis is individual participant (IPD) meta-analysis, which utilises original raw 10 
data for the analysis. The key benefits of this type of analysis are the ability to better harmonise 11 
primary risk factors and outcomes between studies, the adjustment of identical confounders, the 12 
application of consistent inclusion and exclusion criteria, and the ability to include previously 13 
unpublished datasets into the analysis (3-5). 14 
 15 
The critical limitation of traditional meta-analyses is the reliance upon the individual cohort 16 
definition of OA, some of which are over 50 years old. A diagnosis of OA is commonly established 17 
using radiographic features alone or in combination with joint pain, often defined using NHANES 18 
(National Health and Nutrition Examination Survey) type or WOMAC (Western Ontario and 19 
McMaster Universities Arthritis Index) questions (6). Many cohorts lack objective clinical 20 
assessment, which prevents the use of the American College of Rheumatology (ACR) criteria and 21 
the identification of pre-radiographic OA. More recently, self-reported pain, regardless of 22 
radiographic OA (ROA), has been used to measure disease burden. There are multiple ways to 23 
assess both radiographic OA and OA-related joint pain, and the comparability of these 24 
measurements is not yet completely understood. The choice of definition can substantially affect 25 
both OA prevalence and its association with risk factors. This has been demonstrated for ROA 26 
outcomes such as K/L grades and between the use of different individual feature atlases (7). 27 
Previous meetings have focused on defining early OA, however OA was outside the scope of their 28 
recommendations (8, 9). 29 
 30 
The aim of this research was to generate recommendations for combining OA data within existing 31 
and future OA population cohort studies. A committee of international OA experts was convened to 32 
define OA for use in IPD meta-analyses using population-based cohorts. This paper presents the 33 
research and conclusions of the work performed by this committee. 34 
 35 
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Methods 36 
 37 
Identification of key discussion points by the Steering Group 38 
 39 
The steering group consisted of authors KML, LG, and NKA. Due to the variety of questionnaires 40 
and variables used to classify OA, the interest for this study were OA assessments used in 41 
previously collected longitudinal population-based cohort studies with concurrent OA-related pain 42 
and radiographic measures at multiple time points in the hip or knee. Cohorts were excluded if their 43 
non-OA subjects were recruited differently from their OA subjects, or did not have the same pain 44 
and ROA data available. Potential cohort studies were identified using two pathways: 1) literature 45 
review and 2) direct contact with principal investigators (PIs) of known osteoarthritis cohorts. The 46 
literature review sought to identify both cohorts matching the exact inclusion criteria, but also 47 
cohorts which appeared likely to have the data of interest (i.e. a published cross-sectional analysis 48 
of knee pain with indications that longitudinal and ROA data may exist) (appendix 1). Contact with 49 
PIs began with researchers with whom we had previous collaborative relationships, requesting their 50 
own unpublished variables and datasets along with any knowledge of additional cohorts matching 51 
the inclusion criteria.  Additional PIs and datasets were identified through specialist OA meetings 52 
and conferences.  53 
 54 
A comprehensive evaluation of OA variables available within the identified population-based and 55 
enhanced risk factor cohorts at baseline time-points, was undertaken by examining data 56 
dictionaries, liaising with cohort members or reviewing published cohort material. Cohorts were 57 
further excluded if their raw data and/or detailed data dictionaries were unavailable or inaccessible 58 
to the steering committee. Information was gathered to determine how each cohort utilised these 59 
OA variables in applied research and their methods of defining end-stage OA. Five key areas 60 
(outlined below) were identified as lacking sufficient published evidence to make decisions on 61 
combining OA data between data sources, and therefore opinions from international OA experts 62 
was sought.   63 
 64 
Selection and endorsement of the Osteoarthritis Expert Committee 65 
 66 
The definition and harmonisation of OA variables was determined within an expert group meeting. 67 
Participants contributed expert opinion on the key discussion points of the study (via video 68 
conference and email), recommended new statistical analyses, provided guidance on the post-hoc 69 
analyses, and contributed critical input on the manuscript. The panel consisted of multidisciplinary, 70 
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geographically diverse experts on OA and population-based cohort studies. Experts were selected 71 
based upon meeting one or more of the following criteria: 72 
 73 
• Investigators with experience leading population cohorts who have an advanced knowledge 74 
of OA and thorough understanding of epidemiological cohort data collection 75 
• Representatives with experience in producing guidelines for musculoskeletal disease 76 
definitions or investigative imaging techniques 77 
• Members of the original IPD meta-analysis steering group to provide expertise and context 78 
for how the harmonised OA variable would be used for future research 79 
 80 
Sixteen experts were invited to participate in the entire study. Nine of these attended the meeting by 81 
video link. All Sixteen contributed to the definition of new statistical analyses, the post hoc analysis 82 
and contributed to the manuscript. 83 
 84 
The expert committee’s work has been endorsed by Osteoarthritis Research Society International 85 
(OARSI), International Osteoporosis Foundation (IOF), European Society for Clinical and 86 
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the British Association of Sport 87 
and Exercise Medicine (BASEM). 88 
 89 
Meeting format 90 
 91 
The process consisted of the following steps: 1) First steering committee meeting held in November 92 
2014, where the decision was made to hold an expert meeting to address issues with existing OA 93 
data and produce recommendations for future research 2) Experts were contacted via email with 94 
aims and objectives of the meeting, points for discussion and all relevant background material 95 
identified by the steering committee including a summary of the type of variables each cohort 96 
appeared to contain from published literature and/or open access online data dictionaries; 3) A 97 
meeting was conducted in April 2015, using a structured discussion surrounding the five key points, 98 
led by NKA and KML; 4) Discussions on each point continued until agreement was reached using 99 
an iterative process, or it was determined that further action and/or information was required in 100 
order to reach agreement, which was provided by steering committee members; 5) A document 101 
containing the results from the April meeting along with the further recommended analysis was fed 102 
back to the group via email, with all experts indicating agreement, disagreement, or modification 103 
(November 2015); 6) To account for potential negative group dynamics, dissenting opinions could 104 
be voiced directly to the steering committee, where it was anonymously added to the feedback 105 
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document for discussion by all experts;  7) Final decisions were agreed via email by October 2015 106 
8) First draft of manuscript produced in June 2016. 107 
 108 
Five key discussion points 109 
 110 
1. To determine the criteria to classify OA in population-based cohort studies 111 
2.  To determine the comparability of existing NHANES-type pain questions, which contain 112 
wording variations 113 
3. To assess whether previously published thresholds used to determine pain using the 114 
WOMAC scale were appropriate for research, and determine comparability with the 115 
NHANES-type pain questions 116 
4. To review the comparability of radiographic scoring methods and establish the ‘best’ 117 
measure to use based on available data 118 
5. To assess the usability and comparability of alternate OA outcomes: self-reported OA, GP 119 
diagnosis, and joint replacement for OA 120 
 121 
Results 122 
 123 
1. To determine the criteria to classify OA in population-based cohort studies 124 
 125 
Potential definitions of OA (radiographic, symptoms alone or symptomatic radiographic) were 126 
presented with supporting evidence to the expert committee for discussion.  127 
 128 
Expert Discussion 129 
 130 
The committee recognized that there has been a shift toward the importance of pain as a driving 131 
factor in the definition of OA, rather than structural factors alone.  However, due to the risk of 132 
misclassification it was felt that the combination of symptoms and structural features would provide 133 
the most accurate definition. The committee also considered that symptoms alone, without 134 
radiographic data, could be an important aspect of the OA definition. Due to the lack of 135 
standardization and reliability of pain assessments available at multiple time-points, it was agreed 136 
that self-reported pain questions should not be used alone in the current state of knowledge.  137 
 138 
Decision 139 
 140 
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Experts agreed to use symptomatic radiographic OA as the primary criteria to classify OA for the 141 
purpose of combining OA classifications across cohort studies.  Pain alone was suggested as a 142 
secondary criterion. When defining pain, experts agreed that a binary, self-reported, joint-specific 143 
pain question would provide the best definition of OA-related symptoms in the majority of the 144 
population-based cohorts. 145 
 146 
2. To establish the comparability of existing NHANES-type pain questions which contain 147 
wording variations 148 
 149 
The committee was provided with details of the wording variation found in pain questions 150 
commonly used in population based studies to identify OA-related joint pain. NHANES in the 151 
1970’s used the question: “Have you ever had pain in or around a knee on most days for at least a 152 
month?” (10); a second question was added in the 1990’s: “Have you had (any) pain in or around 153 
your knee for at least a month in the last year?”. The ACR used a modified version of the question 154 
as part of criteria to diagnose OA: “Have you had (knee/hip) pain on most days in the last month?”. 155 
 156 
A wide range of these types of questions, with a variety of wording, was found among the 157 
international cohorts containing OA (appendix 2). The differences between these questions occurs 158 
in two places: first, the amount of time reported with pain (i.e. any, most days in the last month) and 159 
second, the period of recall (i.e. in the last month, last year, ever). In order to simplify a comparison 160 
between questions, they were grouped into five types by the steering group, where both the amount 161 
of time with pain and the period of recall were as similar as possible (figure 1).  162 
 163 
Figure 1 164 
 165 
Expert Discussion 166 
 167 
Of the five variations of NHANES-type questions identified in the cohorts (figure 1), the two 168 
most commonly used were: A) most days in the last month and C) at least a month in the last 169 
year. The committee agreed that questions A-D appeared similar enough to be combined, 170 
however, question E (pain for at least a month ever) was deemed to be too different to be 171 
combined and that it should be analysed as part of a sensitivity analysis if necessary. Previous 172 
research by O’Reilly et al (11) compared three different variations of NHANES-type questions 173 
and found that knee pain prevalence varied between 19.3% and 28.3% depending on the 174 
questions. Two of these questions were comparable to our NHANES A and C variations, with 175 
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their reported prevalence differing by six percentage points (11). These results showed that 176 
although overall agreement was good, the estimates of knee pain are influenced by even minor 177 
changes in the wording of the question.   178 
 179 
The committee ultimately decided that not enough was known to make an informed decision 180 
and suggested original research into the topic before making a final decision. In order to 181 
provide the necessary evidence, the steering group therefore undertook an analysis of these 182 
NHANES-type questions using an OA-related cohort (Action A), which was then reviewed by 183 
the full expert committee.  184 
 185 
Action A 186 
 187 
The experts suggested that the Multicenter Osteoarthritis Study (MOST) was the best cohort to 188 
examine the relationship of OA-pain assessments as it contains multiple NHANES questions at the 189 
same time point. The MOST study is a US-based observational study of subjects with or at high risk 190 
for knee OA recruited in 2003 with a greater number of subjects with high BMI, family history of 191 
OA and/or knee pain (12). Participants at baseline answered four binary NHANES-type questions: 192 
A) Knee pain on most days in the last month; B) Any knee pain in the last month; C) Knee pain 193 
lasting at least a month in the last year; D) Any knee pain in the last year. Sensitivity, specificity 194 
and area under the curve (AUC) from ROC curves were used to compare NHANES-type questions. 195 
NHANES A was selected as the reference question due to its similarity to the pain assessment used 196 
as part of the ACR OA diagnostic criteria, it was one of the more commonly used pain questions in 197 
the OA cohort studies, and it has been previously been used as part of a gold-standard definition of 198 
SROA to test the performance of ACR criteria in the general population (13).  199 
 200 
Out of 3026 subjects, 2922 had all required data at baseline (basic demographics and pain 201 
questions) and were used for the cross-sectional analysis. NHANES A and C showed a similar 202 
prevalence of pain (41.0% and 43.4%), while NHANES B and D both produced a substantially 203 
higher prevalence (67.3 and 75.4%). NHANES C (pain lasting at least a month in the last year) 204 
showed the best sensitivity (91.2%) and specificity (89.9%) against the reference NHANES A, with 205 
both NHANES B and D having very low specificity (55.5% and 41.7% respectively) (table 1). 206 
 207 
Table 1 208 
 209 
Decision 210 
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 211 
The results of the analysis requested by the experts showed that the comparability of questions was 212 
influenced more by the duration of reported pain (i.e. pain lasting at least a month) than the period 213 
of pain recall (i.e. in the last year). NHANES A was felt to be the best wording based upon the 214 
frequency that it is found in OA cohorts, its use as part of the ACR clinical criteria and that the 215 
amount of time and period of recall used to identify pain occurs concurrent with the radiographic 216 
information. NHANES C had the best sensitivity and specificity for NHANES A, and was therefore 217 
identified as the most appropriate option in the instance of using existing data, where NHANES A 218 
is not available. 219 
 220 
3. To assess whether previously published thresholds used to determine pain using the 221 
WOMAC scale are appropriate for research and determine comparability with the NHANES-222 
type pain questions 223 
 224 
The WOMAC is commonly used in addition to, or instead of, NHANES-type questions in OA-225 
related population-based cohorts. It was felt important to investigate whether the WOMAC index 226 
could be used as an alternative pain measure. The WOMAC index is a standardized set of questions 227 
developed to evaluate knee or hip pain, function and disability (14). WOMAC pain scores are used 228 
as continuous measure (range 0-20).  229 
 230 
Expert Discussion 231 
 232 
Experts agreed that a threshold for WOMAC was needed so that all cohorts could be included into 233 
the IPD meta-analysis. Several issues were identified when using a threshold with a WOMAC scale 234 
to be comparable to NHANES-type questions, including that only the pain sub-scale, would be 235 
equivalent and that the period of recall for pain was not given in early versions of WOMAC (pre 236 
3.0). It was thought that previous research where thresholds had been used (15-17) were not 237 
appropriate for current population cohorts due to their development primarily in, and for, clinical 238 
outcomes in patient populations. The committee believed that a threshold should be developed 239 
specifically for combining the data with the NHANES-type questions and suggested further work 240 
before an ultimate decision was made (Action B).  241 
 242 
Action B 243 
 244 
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The MOST study (see Action A for cohort description) was used for this analysis. In addition to the 245 
NHANES-type questions assessed at baseline, participants completed the WOMAC pain sub-scale 246 
(range 0-20) asking for pain during daily activity in the past 30 days. A cut-point was established 247 
for the WOMAC pain sub-scale against the reference question (NHANES A), at the point at which 248 
sensitivity and specificity were closest together. 95% confidence intervals (CI) around the cut-249 
points were estimated using bootstrap methods with 300 repeats. The Osteoarthritis Initiative cohort 250 
(OAI), which has similar inclusion criteria to MOST and is also an enhanced risk factor population-251 
based cohort, was used to validate the WOMAC threshold against the gold-standard question using 252 
identical inclusion/inclusion criteria and statistical methods. OAI used the WOMAC pain sub-scale 253 
asking for pain during daily activity in the past 7 days. 254 
 255 
The WOMAC pain sub-scale had a median of 2 (IQR 0, 6), and a cut point of 3 was found using 256 
both NHANES A (3 (95% CI 2.1, 3.9)) and C (3 (95%CI 2.8, 3.2)). When this cut-point was used to 257 
create a binary pain variable from the WOMAC pain sub-scale, the sensitivity and specificity of this 258 
new variable against the NHANES A question was 83.6% and 76.0%, respectively (table 2). In the 259 
OAI validation cohort (n=4,723), the WOMAC pain sub-scale had a median of 1 (IQR 0, 4) and 260 
also generated a cut-point of 3 (95% CI 2.3, 3.7). 261 
 262 
Table 2 263 
 264 
Decision 265 
 266 
Action B analysis demonstrated that a cut-point of 3 in the WOMAC pain sub-scale had the best 267 
sensitivity and specificity against the gold standard NHANES question ‘pain on most days in the 268 
previous month’. The same cut-point of greater than or equal to 3 was found in the OAI validation 269 
cohort. Experts agreed that this threshold could be applied in cohorts where only WOMAC pain 270 
data was available to generate the symptomatic radiographic OA variable.  271 
 272 
4. To assess the comparability of methods used to grade radiographic OA and determine the 273 
‘best’ measure to use based on available data  274 
 275 
There are a number of scoring methods to semi-quantitatively assess radiographic OA. Two of the 276 
most used in population-based cohorts are the K/L (a global grade) and the OARSI atlas of 277 
individual features which records features such as joint space narrowing and osteophyte size for 278 
each joint location (18, 19). Neogi et al found that in a within person matched case-control study 279 
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that K/L grade had a higher association with knee pain than either osteophytes or joint space 280 
narrowing alone (20). Most of the cohorts in our consortium used a K/L grade, however there is 281 
known variation between different versions of the grade. Kerkhof et al (7) found that the actual 282 
definition of K/L grade 2+ significantly varied across cohorts which substantially affected OA 283 
prevalence. Experts were presented with the x-ray views and scoring methods used in each cohort 284 
in order to inform decision making on the most appropriate scoring method and thresholds for 285 
determining radiographic OA in existing cohort studies.   286 
 287 
Expert Discussion and Decision 288 
 289 
The committee felt that the K/L grade should be used as it was available in the majority of the 290 
cohorts, and they did not feel a ‘computed’ grade (calculated using individual features of 291 
osteophytes and joint space narrowing) would add any benefit above and beyond K/L. All experts 292 
agreed that using the established cut-off for radiographic OA, K/L greater than or equal to 2 was 293 
appropriate for this current research to define more advanced stages of OA, rather than an alternate 294 
cut-off or individual features. However, there was interest in exploring the use of K/L as an ordinal 295 
measure in future research if the grading was found to be comparable between cohorts. The 296 
committee felt that the inclusion of the patellofemoral compartment was extremely important and 297 
were disappointed that it could not be included in this research due to the lack of data. For future 298 
research, the inclusion of the patellofemoral compartment was identified as a key area of 299 
improvement, in addition to the use of a high quality standardised atlas (such as the OARSI atlas) to 300 
grade at least osteophytes and joint space narrowing as individual radiographic features (19).  301 
 302 
5. To assess the usability and comparability of alternate OA outcomes: self-reported OA, GP 303 
diagnosis, and joint replacement 304 
 305 
Community-based cohort studies where OA and/or musculoskeletal conditions are not the primary 306 
interest often lack NHANES/WOMAC pain assessment and radiographic OA information, but may 307 
include questions relating to self-reported OA or to total joint replacement surgery (TJR). The 308 
addition of these types of cohorts increases the number of subjects and often provides more detailed 309 
risk factors. Two common variations of this type of question relate to self-perceived arthritis: “Do 310 
you have (knee/hip) osteoarthritis?” and self-reported physician diagnosed OA: “Have you ever 311 
been told that you have OA of your knee (hip) by a doctor?” Although evidence is limited, there is a 312 
known lack of comparability between these two question variations. Szoeke et al (21) demonstrated 313 
that within the same cohort of patients, 63.7% reported self-perceived arthritis versus 48.7% self-314 
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reported physician diagnosed OA. More encouragingly, self-reported clinician diagnosed OA (hip 315 
and knee) has been found to have high positive predictive value (98% and 91%) when compared 316 
with clinical OA, as defined by ACR criteria (22).  317 
 318 
Expert Discussion and Decision 319 
 320 
The expert committee felt the ‘self-perceived’ measure would be more problematic for hip OA than 321 
knee OA, and suspected there would be little correlation between self-perceived OA and TJR. Joint 322 
replacement is also limited by variability in healthcare access across different countries and 323 
societies, and region and time-dependent variable contribution of indications other than OA for 324 
TJR, such as rheumatoid arthritis, fracture, and osteonecrosis. The experts agreed that further 325 
research, in cohorts with both variables reported to allow comparisons, was required before making 326 
a final decision. 327 
 328 
Strengths and limitations 329 
 330 
This study has several strengths; it is the first to create a standardised definition of knee and hip OA 331 
for use in combining data from cohort studies, which is becoming increasingly important to answer 332 
important questions in OA.  We have demonstrated the importance of the exact wording of 333 
NHANES type questions and further more generate an equivalent WOMAC score for populations 334 
where NHANES questions are not recorded.  The use of a comprehensive collection of existing 335 
cohort data and inclusion of the study PIs in addition to international experts facilitated the decision 336 
making process.  337 
 338 
It also has several potential limitations. The cohorts included in this analysis are a subset which 339 
meet the inclusion criteria and may not contain the full range of OA assessments found in existing 340 
longitudinal population-based OA cohort studies.  341 
 342 
Furthermore, the generation of “NHANES equivalent scores” using WOMAC, may allow the 343 
incorporation of other cohorts, however for the purpose of this study it was important to capture 344 
those with both symptomatic and radiographic knee and/or hip OA data and we do not feel that 345 
inclusion of additional cohorts would affect the results of this paper.  The group of “experts”, 346 
although covering most important stakeholders, may not have been complete, however we feel that 347 
due to the wide experience of the group in similar committees and processes mean that it is unlikely 348 
that the addition of other stakeholders would have changed our results.  349 
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 350 
Summary and Recommendations 351 
 352 
This international study is the first to describe methods to define and harmonise OA data for 353 
population-based cohort studies. Combining OA data allows for the application of novel research 354 
techniques, such as IPD meta-analysis in existing studies as well as informing data collection 355 
recommendations for future OA cohorts.  356 
 357 
This research has highlighted the disparity of OA data in existing cohort studies, making 358 
comparisons between cohorts and interpretation of previous research difficult.  The effect of using 359 
different radiographic atlases, questionnaires and even the wording of OA related pain questions are 360 
important considerations when comparing OA data.    361 
 362 
Recommendations for combining extant OA data  363 
 364 
• Use a combination of symptoms and radiographic features to define OA as a primary 365 
outcome, or by symptoms alone when radiographic data is lacking 366 
• Where possible, use NHANES-type questions where duration of pain is indicated as ‘most 367 
days in a month’ (NHANES A and NHANES C), due to wide variation in pain prevalence 368 
which was found depending on the question wording 369 
• If a WOMAC pain subscale (0-20) is available, rather than NHANES question, a cut point 370 
of 3 or more can be used to reasonably equate to NHANES A or C questions  371 
• For defining radiographic OA, experts recommended the use of a K/L grade 2 and above,  372 
• Caution is recommended when trying to combine self-reported GP OA diagnoses or self-373 
perceived OA, as the relationship between these is unknown. Experts believe these variables 374 
may be very different from symptomatic radiographic OA, and therefore require further 375 
research 376 
 377 
Recommendations for collecting new OA data in cohort studies  378 
 379 
• Use multiple pain assessments (i.e. NHANES pain question, WOMAC, clinical assessment, 380 
etc.) at multiple time-points to provide better comparability with existing cohorts and to use 381 
as outcome measures 382 
• Include self-reported/GP-diagnosed OA and pain questions 383 
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• Use additional x-ray views (i.e. the patello-femoral compartment) to improve diagnosis of 384 
radiographic knee OA 385 
• Record individual radiographic features (i.e. using OARSI atlas of individual features) in 386 
addition to K/L grades 387 
• Wording of pain questions should be consistent for the duration of pain asked. ‘Most days 388 
of the month’ is the most commonly used wording in existing cohort studies. 389 
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Appendix 1. Summary of the cohorts included within consensus study and potential OA variables identified within each 
Cohort Self 
reported 
clinician 
diagnosed 
Self 
perceived 
OA 
TJR Knee x-ray  NHANES- type questions WOMAC 
 
  
 
 1 2 3 4 5  
OAI         
 
  
  
 
MOST               
SOF         
    
  
ROAD     
  
 
  
 
Herts       
     
Johnston  
County 
 
      
   
     
TasOAC     
     
 
Chingford    (hip only)  (hip)    
    
Framingham      
  
 
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Appendix 2. Wording variations of the binary NHANES-type pain questions found within the 
MILOS consortium cohorts 
NHANES-Type Questions  
“Pain, aching or stiffness in or around the knee most days” for at least 1 month of the past 12 
months.  
“ [Any] Pain, aching, stiffness in (left/right)knee in past 12 months?”  
“Pain, aching, stiffness in (right/left) knee on most days for more than 1 month in the last 12 
months?”  
“Pain, aching, stiffness on most days in the last month?”  
NHANES I questionnaire “Have you ever had pain in or around your knee on most days for at least 
a month?”  
“(Left/Right) Knee pain lasting at least a month during last 12 months”  
“Knee pain lasting at least one month in the current or previous year”  
“Number of months with knee pain for each year in the past 12 years since baseline visit”  
“Have you had pain in or around your (left/right) knee on most days in the last month?”  
“On most days do you have pain, aching or stiffness in your KNEES?”  
“Have you had pain on most days of the last month?”  
“Have you ever had pain in your knees for more than one month?”  
“Have you had (any) knee pain within the last month?”  
“Did you have [any] (knee/hip, R/L) pain in the last month?” “If yes, on how many days (0-5, 5-15, 
15+)”  
“Ever pain lasting at least one month (in previous 2 years)”  
 1 
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Table 1. Comparison of NHANES-type pain questions within the MOST cohort 
  Prevalence (N) Sensitivity Specificity AUC (95% CI) 
NHANES A 41.0% (1198) Reference Reference Reference 
NHANES B 67.3% (1966) 100.0% 55.5% 0.78 (0.77, 0.79) 
NHANES C 43.4% (1267) 91.2% 89.9% 0.91 (0.90, 0.92) 
NHANES D 75.4% (2203) 100.0% 41.7% 0.71 (0.70, 0.72) 
 
NHANES A “Knee pain on most days in the last month”  NHANES B “Any knee pain in the 
last month”; NHANES C “Knee pain lasting at least a month in the last year”; D “Any knee 
pain in the last year” 
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Table 2. WOMAC thresholds (0-20 scale with 20 reflecting severe pain), and prevalence, sensitivity, and specificity after applying 
thresholds 
 
Cut point  
(Against NHANES A) 
Applying a cut point of 3  
(Tested against NHANES A) 
  
 Prevalence (N) Sensitivity Specificity AUC (95% CI) 
MOST 3 (95% CI 2.1, 3.9) 48.4% (1415/2922) 83.6% 76.0% 0.80 (0.78, 0.81) 
OAI 3 (95% CI 2.3, 3.7) 35.9% (1695/4723) 70.7% 79.7% 0.75 (0.74, 0.77) 
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Figure 1. NHANES questions grouped into similar duration of pain and periods of recall 
*’Month’ can represent the following: ‘most days of a month’, ‘at least a month’ or ‘more 
than a month’ 
 
